Vaginal dryness: causes and what helps— based on 43 stories and medical guidance

Vaginal dryness means there is less natural lubrication than usual. It can feel like burning, itching, irritation, pain or discomfort during sex¹². It is a common complaint: according to Cleveland Clinic, dryness affects more than 15% of women before menopause and more than half after it².

If the cause is menopause. When dryness is linked to falling oestrogen, doctors speak of genitourinary syndrome of menopause. In 2014 this term replaced “vulvovaginal atrophy”⁶. It includes dryness, burning, irritation, reduced lubrication, pain during sex, as well as frequent urges to urinate and recurrent urinary tract infections⁶. The syndrome affects 27–84% of postmenopausal women and is probably underdiagnosed and undertreated⁵. The British Menopause Society describes it as a chronic condition: without treatment it gets worse over time and usually appears 3–5 years after menopause. Many women consider it “normal ageing” and do not tell their doctor⁴.

Other causes, according to the NHS and Cleveland Clinic¹²:

• pregnancy and breastfeeding: hormone levels change;
• hormonal contraception;
• some antidepressants;
• cancer treatment: chemotherapy, radiotherapy, hormone therapy, surgery, removal of the ovaries or womb;
• Sjögren’s syndrome, diabetes, lupus, lichen planus¹²²³;
• not enough arousal, stress, alcohol, smoking;
• scented soaps, gels and douching.

After childbirth. In a systematic review of 65 studies, vaginal dryness occurred in 53.6% of breastfeeding women after childbirth. The authors link it to hormonal changes during lactation²¹ and propose a separate term, “genitourinary syndrome of lactation”²². In a 2008 study, exclusive breastfeeding was associated with pain during sex after childbirth²⁴.

Lubricants — during sex. The NHS recommends a water-based lubricant¹. The British Menopause Society allows water-based, silicone and oil-based ones, by preference, but warns that oil-based lubricants weaken condoms⁴. There is little evidence on lubricants themselves: in a review for the WHO, one randomised trial showed that they improve women’s sexual well-being (moderate certainty), while the data on pain and dryness are only observational, with very low certainty¹⁹.

Ingredients matter. According to the WHO, the osmolality of vaginal fluid is 260–290 mOsm/kg; for a lubricant it should ideally be no higher than 380, with an interim procurement limit of 1,200. Most commercial lubricants are at 2,000–6,000. The pH for vaginal use is around 4.5²⁰. High-osmolality lubricants damaged tissue in laboratory studies, although there is no direct clinical evidence of harm to the vagina in people with dryness; the WHO document was written for procuring lubricants to use with condoms²⁰. Glycerin can feed Candida yeast, and a moisturiser is best chosen without parabens and with an acidic pH¹⁸. A link between parabens and breast cancer has not been proven¹⁸.

Moisturisers — regularly, separate from sex. The NHS recommends vaginal moisturisers¹, Cleveland Clinic suggests using them every few days², and the British Menopause Society at least twice a week; it considers them comparable in effectiveness to local oestrogen⁴. For women with a history of breast cancer, ACOG puts non-hormonal products first and notes that none of them is best and sometimes several have to be tried¹⁰. The evidence is mixed: in a randomised trial of 302 women over 12 weeks, neither a moisturiser nor an estradiol tablet did better than a placebo gel⁸, and a review of 46 studies says moisturisers “may reduce dryness”, with low certainty⁹. In a review of 5 studies (335 women), hyaluronic acid did not differ from oestrogens¹⁶; another review calls it “generally effective” but asks for higher-quality studies¹⁷.

Local oestrogen. This means estradiol tablets or pessaries, a ring, or an estriol cream or gel⁴⁵. A Cochrane review (30 studies, 6,235 women) showed that all forms are better than placebo, with no difference between them, although the quality of evidence is low to moderate⁷. NAMS considers local oestrogen effective for moderate to severe symptoms and does not require adding a progestogen⁵. The British Menopause Society, citing NICE 2024, says it can be used for as long as needed, with an annual review. Improvement comes in the first weeks, the full effect later⁴. Systemic hormone therapy on its own does not always relieve the symptoms, and local treatment is then added⁴. Which medicine, in which form and on which regimen is for the doctor to decide.

After breast cancer. ACOG advises starting with non-hormonal products. If they have not helped, low-dose vaginal oestrogen is possible, including on tamoxifen, and on aromatase inhibitors only as a joint decision with the oncologist¹⁰. The British Menopause Society also requires the decision to be made together with an oncologist⁴. A study of 49,237 women in Scotland and Wales found no increase in breast cancer mortality¹¹, and one in the USA (42,113 women) found no increase in recurrences over 5 years¹³. In Denmark (8,461 women), recurrences were not more frequent overall, but they were more frequent in women on aromatase inhibitors¹². All these studies are observational.

Other options prescribed by a doctor. Prasterone is vaginal DHEA: in a phase III trial it reduced pain during sex and dryness compared with placebo¹⁴⁵. Ospemifene is a tablet for those who cannot use or do not want vaginal products; side effects include hot flushes, and it is used with caution in thrombosis⁴¹⁵. There is not enough evidence for laser: NAMS does not recommend it⁵, and in the UK it is used only in research⁴. If pain during sex is linked to muscle tension from expecting pain, the British Menopause Society recommends a pelvic floor physiotherapist⁴.

Lifestyle. Stop smoking; regular sexual activity improves blood flow and tissue elasticity⁴. More time for foreplay, and no scented products in the intimate area¹.

We analysed 43 discussions and personal stories involving around 300 people: 32 threads from the British forum Mumsnet, 4 from forums for breast cancer patients, 2 from the American sexual health website Scarleteen, 1 from Offbeat Home and 4 personal stories in the media and on blogs. The unit of count is one thread or one story. An approach was counted if at least one participant described personal experience with it; advice without personal experience was not counted. Collected on 11 November 2026.

All 43 stories are in English. We were unable to analyse Russian- and Ukrainian-language discussions: the largest forums are protected by “are you a robot” checks, and we chose not to bypass them; on other platforms, search did not return pages with personal experience. We did not use Reddit either. As a result, the sample is dominated by middle-aged British women, menopause and prescription treatment within the British health system. There are few stories from younger women or about contraception, antidepressants and Sjögren’s syndrome. Access to doctors and medicines in Ukraine is different. Ukrainian and Russian clinical guidelines were not checked in this research.

One more piece mentioning brands looked like native advertising. We did not count it, just as we do not count sources with a commercial interest; this does not change the conclusions. One story was written by a minor, and we do not use retellings from it. Coding was done by hand, with a possible error of 1–2 discussions. People’s experience is not statistics: we show how many discussions mention something, not what percentage of women experience it. Medical facts come only from medical and scientific sources, each numbered in the list.